|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Voyager Therapeutics
| | | Phone: | (857) 259-5340 | Year Established: | 2014 | Ticker: | VYGR | Exchange: | NASDAQ | Main Contact: | Allison Dorval, VP, Finance | | Other Contacts: | Matthew P. Ottmer, COO Jim Olesen, Ph.D., VP, IP & Legal Affairs John Connelly, VP, Program and Alliance Management Bernard Ravina, MD, CMO Dinah Sah, Senior VP, Neuroscience Robert Pietrusko, Pharm.D., Senior VP, RA G. Andre Turenne, President & CEO
| | Company Description | Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing and delivery techniques, as well as process development and production. The company’s pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia and Huntington’s disease. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. | |
|
|
|
|
|